The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study

Journal of Affective Disorders

Volumn 225, Issue , 2018, Pages 350-356

  Ketter, Terence A ^a   Sachs, Gary S ^b   Durgam, Suresh ^c   Lu, Kaifeng ^c   Starace, Anju ^c   Laszlovszky, István ^d   Németh, György ^d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c ALLERGAN INC   (United States)

^d GEDEON RICHTER LTD   (Hungary)

Author keywords

Atypical antipsychotic; Bipolar disorder; Cariprazine; Longer term safety; Mania; Tolerability

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BENZATROPINE; BILIRUBIN; CARIPRAZINE; CHLORAL HYDRATE; CHOLESTEROL; CREATINE KINASE; DIPHENHYDRAMINE; ESZOPICLONE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LORAZEPAM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROLACTIN; PROPRANOLOL; TRIACYLGLYCEROL; ZALEPLON; ZOLPIDEM; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ADULT; AGED; AKATHISIA; ANXIETY; ARTICLE; BIPOLAR I DISORDER; BIPOLAR MANIA; BLURRED VISION; CATARACT; CONSTIPATION; DEPRESSION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSPEPSIA; ELECTROCARDIOGRAM; ELEVATED BLOOD PRESSURE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; INCIDENCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MANIA; MONTGOMERY ASBERG DEPRESSION RATING SCALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; RESTLESSNESS; SEDATION; SIDE EFFECT; SOMNOLENCE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; TOOTH PAIN; TREATMENT DURATION; TREMOR; VITAL SIGN; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; YOUNG MANIA RATING SCALE; BIPOLAR DISORDER; BODY WEIGHT GAIN; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 85028015895     PISSN: 01650327     EISSN: 15732517     Source Type: Journal    
DOI: 10.1016/j.jad.2017.08.040     Document Type: Article

References (29)

1. APA, Diagnostic and Statistical Manual of Mental Disorders, Fourth ed., Text Revision ed., 2000, American Psychiatric Association, Washington DC.
2. Barnes, T.R., A rating scale for drug-induced akathisia. Br. J. Psychiatry 154 (1989), 672–676.
3. Calabrese, J.R., Keck, P.E. Jr., Starace, A., Lu, K., Ruth, A., Laszlovszky, I., Nemeth, G., Durgam, S., Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J. Clin. Psychiatry 76 (2015), 284–292.
4. Cha, D.S., McIntyre, R.S., Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin. Pharmacother. 13 (2012), 1587–1598.
5. Cutler, A.J., Wang, Y., Migliore, R., Lu, K., Laszlovszky, I., Nagy, K., Durgam, S., 2014. Safety and tolerability of cariprazine in the long-term treatment of schizophrenia. Poster presented at In: Proceedings of the 4th Biennial Schizophrenia International Research Conference; April 5–9, 2014; Florence, Italy.
6. Durgam, S., Greenberg, W.M., Li, D., Lu, K., Laszlovszky, I., Németh, G., Migliore, R., Volk, S., Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study. Psychopharmacology 234 (2017), 199–209.
7. Durgam, S., Starace, A., Li, D., Migliore, R., Ruth, A., Németh, G., Laszlovszky, I., The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 17 (2015), 63–75.
8. First, M.B., Williams, J.B.W., Spitzer, R.L., Gibbon, M., Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Clinical Trials Version (SCID-CT). Biometrics Research. 2007, New York State Psychiatric Institute, New York.
9. Gao, K., Kemp, D.E., Ganocy, S.J., Gajwani, P., Xia, G., Calabrese, J.R., Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J. Clin. Psychopharmacol. 28 (2008), 203–209.
10. Geddes, J.R., Miklowitz, D.J., Treatment of bipolar disorder. Lancet 381 (2013), 1672–1682.
11. Goldstein, B.I., Fagiolini, A., Houck, P., Kupfer, D.J., Cardiovascular disease and hypertension among adults with bipolar I disorder in the United States. Bipolar Disord. 11 (2009), 657–662.
12. Guy, W., The Abnormal Movement Scale. ECDEU Assessment Manual for Psychopharmacology. 1976, National Institute of Mental Health, Rockville, MD, 218–222 DHEW Publication No. 76–338.
13. Guy, W., The Clinician Global Severity and Impression Scales. ECDEU Assessment Manual for Psychopharmacology. 1976, National Institute of Mental Health, Rockville, MD, 218–222 DHEW Publication No. 76–338.
14. Judd, L.L., Akiskal, H.S., Schettler, P.J., Endicott, J., Maser, J., Solomon, D.A., Leon, A.C., Rice, J.A., Keller, M.B., The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch. Gen. Psychiatry 59 (2002), 530–537.
15. Kane, J.M., Fleischhacker, W.W., Hansen, L., Perlis, R., Pikalov, A. 3rd, Assuncao-Talbott, S., Akathisia: an updated review focusing on second-generation antipsychotics. J. Clin. Psychiatry 70 (2009), 627–643.
16. Ketter, T.A., Amchin, J., Frye, M.A., Gross, N., Long-term safety and efficacy of armodafinil in bipolar depression: a 6-month open-label extension study. J. Affect. Disord. 197 (2016), 51–57.
17. Ketter, T.A., Sarma, K., Silva, R., Kroger, H., Cucchiaro, J., Loebel, A., Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study. Depress Anxiety 33 (2016), 424–434.
18. Kilbourne, A.M., Cornelius, J.R., Han, X., Pincus, H.A., Shad, M., Salloum, I., Conigliaro, J., Haas, G.L., Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord. 6 (2004), 368–373.
19. Kiss, B., Horváth, A., Némethy, Z., Schmidt, E., Laszlovszky, I., Bugovics, G., Fazekas, K., Hornok, K., Orosz, S., Gyertyán, I., Ágai-Csongor, E., Domány, G., Tihanyi, K., Adham, N., Szombathelyi, Z., Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J. Pharmacol. Exp. Ther. 333 (2010), 328–340.
20. Leboyer, M., Kupfer, D.J., Bipolar disorder: new perspectives in health care and prevention. J. Clin. Psychiatry 71 (2010), 1689–1695.
21. Liauw, S.S., McIntyre, R.S., Atypical antipsychotic tolerability and switching strategies in bipolar disorder. Expert Opin. Pharmacother. 11 (2010), 2827–2837.
22. Montgomery, S.A., Asberg, M., A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979), 382–389.
23. Osby, U., Brandt, L., Correia, N., Ekbom, A., Sparen, P., Excess mortality in bipolar and unipolar disorder in Sweden. Arch. Gen. Psychiatry 58 (2001), 844–850.
24. Posner, K., Brown, G.K., Stanley, B., Brent, D.A., Yershova, K.V., Oquendo, M.A., Currier, G.W., Melvin, G.A., Greenhill, L., Shen, S., Mann, J.J., The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am. J. Psychiatry 168 (2011), 1266–1277.
25. Sachs, G.S., Dupuy, J.M., Wittmann, C.W., The pharmacologic treatment of bipolar disorder. J. Clin. Psychiatry 72 (2011), 704–715.
26. Sachs, G.S., Greenberg, W.M., Starace, A., Lu, K., Ruth, A., Laszlovszky, I., Németh, G., Durgam, S., Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, Phase III trial. J. Affect. Disord. 174 (2015), 296–302.
27. Simpson, G.M., Angus, J.W., A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand. Suppl. 212 (1970), 11–19.
28. Yatham, L.N., Kennedy, S.H., Parikh, S.V., Schaffer, A., Beaulieu, S., Alda, M., O'Donovan, C., Macqueen, G., McIntyre, R.S., Sharma, V., Ravindran, A., Young, L.T., Milev, R., Bond, D.J., Frey, B.N., Goldstein, B.I., Lafer, B., Birmaher, B., Ha, K., Nolen, W.A., Berk, M., Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 15 (2013), 1–44.
29. Young, R.C., Biggs, J.T., Ziegler, V.E., Meyer, D.A., A rating scale for mania: reliability, validity and sensitivity. Br. J. Psychiatry 133 (1978), 429–435.